Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Launched by M.D. ANDERSON CANCER CENTER · Apr 30, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at heart-related issues that may occur in adults who have aggressive types of B-cell lymphoma that has either come back after treatment or is not responding to treatment. The study focuses on patients who have received a specific type of therapy called chimeric antigen receptor T cell therapy, also known as CAR-T therapy, which is a newer and advanced form of treatment for certain cancers. The goal is to better understand any heart problems that might arise after this therapy and how to manage them effectively.

To participate in this trial, individuals need to be at least 18 years old and diagnosed with aggressive B-cell lymphoma, including types like diffuse large B-cell lymphoma and transformed follicular lymphoma, among others. There are no specific exclusions, meaning most adults with this diagnosis can join the study. Participants will be monitored for any cardiovascular events following their CAR-T treatment, providing valuable information that could help improve care for future patients. If you're considering this trial, you can expect close attention to your heart health as part of your ongoing treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (\>= 18 years) with a diagnosis of aggressive B-cell lymphoma (such as transformed follicular lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and high-grade B-cell lymphoma), who received standard of care (SOC) chimeric antigen receptor T (CAR-T) cell therapy at MD Anderson Cancer Center
• Exclusion Criteria:
• • None